CLINICIANS in the army and in civilian practice will probably use sulfone drugs with increasing frequency. After extensive use of sulfones for the past 25 years, dapsone (DDS), the parent sulfone, remains foremost in the therapy of leprosy throughout the world.1 Introduction of dapsone into dermatologic practice in the United States 2,3 followed reports describing the salutary effects of the sulfone on certain chronic skin diseases.4,5 Recently, the emergence of falciparum malaria resistant to chloroquine and other synthetic antimalarial drugs 6,7 led to an evaluation of dapsone in the therapy of these refractory strains.8 Results of field trials have encouraged the US Army to add dapsone to their regimen for malaria prophylaxis.9
A consideration of this effective but potentially toxic drug seems timely in view of its rapidly increasing use in civilian and military practice. Since extensive reviews of sulfones have appeared in the literature,1,10-14
DeGowin RL. A Review of Therapeutic and Hemolytic Effects of Dapsone. Arch Intern Med. 1967;120(2):242–248. doi:10.1001/archinte.1967.00300020114017
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: